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Pseudoxanthoma elasticum (PXE) is a heritable connective tissue disorder caused by mutations in an ABC (ATP-
Binding Cassette) transporter gene (ABCC6), which manifests with cutaneous, ophthalmologic, and cardiovascular
ﬁndings. We studied a cohort of 19 families with PXE, and identiﬁed 16 different mutations, nine of which were
novel variants. The mutation detection rate was about 77%. We found that arginine codon 518 was, with the
previously described R1141X and EX23_29del, a recurrently mutated amino acid (11.5% of the mutations detected
for each variant R518Q and R518X). No clear delineation of genotype/phenotype correlation was identiﬁed, and
marked intra-familial variability of the disease was seen in one family. One family with pseudodominant inheritance
displayed three distinct ABCC6 mutations, providing further evidence for the probable exclusive recessive
transmission of PXE. These data contribute to the expanding database of ABCC6 mutations, to the description of
phenotypic variability, and inheritance in PXE, and should be helpful for genetic counselling.
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Pseudoxanthoma elasticum (PXE) is an inherited disorder
involving mainly three organ systems (cutaneous, ocular,
and cardiovascular) with highly variable clinical expression.
Recessive inheritance is common, but dominant inheritance
has been suspected (Pope, 1975; Neldner, 1988; Bergen
et al, 2000). Skin lesions manifest as yellowish papules that
tend to coalesce into plaques of inelastic, redundant, and
sagging skin. These lesions are primarily seen on the neck,
axilla, antecubital fossa, groin, and periumbilical area. They
are often the first clinical manifestations leading to diag-
nosis. The diagnosis is confirmed by the demonstration of
fragmented calcified elastic fibers using the von Kossa stain
in lesional skin. Eye lesions mainly consist of the so-called
angioid streaks, resulting from pathological fractures in the
elastin-rich sheath of the retina (Bruch’s membrane).
Neovascularization, as a complication of angioid streaks,
may cause recurrent hemorrhages and subsequent visual
impairment. Cardiovascular involvement manifests as early
arteriosclerosis, occlusive vascular changes, and rupture of
blood vessels (particularly within the gastrointestinal tract)
with considerable morbidity (Neldner, 1988; Lebwohl et al,
1993).
Recently, several groups identified ABCC6, an ATP-
binding cassette transporter gene encoding a multidrug
resistance protein (MRP6), as the defective gene in PXE
(Bergen et al, 2000; Le Saux et al, 2000; Ringpfeil et al,
2000; Struk et al, 2000). To date, 57 mutations have been
identified in patients with PXE (Bergen et al, 2000; Le Saux
et al, 2000, 2001; Ringpfeil et al, 2000, 2001; Struk et al,
2000; Cai et al, 2001; Meloni et al, 2001; Uitto et al, 2001; Hu
et al, 2003). ABCC6 is mostly expressed in human liver and
kidneys at both mRNA and protein levels (Kool et al, 1999;
Scheffer et al, 2002), and to a lesser extent in human tissues
affected with PXE (Bergen et al, 2000). In vitro studies
(Belinsky et al, 2002; Cai et al, 2002; Ilias et al, 2002) have
shown that mutations in ABCC6 lead to impaired transport
of glutathione conjugates, but the physiological metabo-
lite(s) actively transported by MRP6 are not yet identified.
Results and Discussion
Mutation detection Sixteen pathogenic mutations were
identified in the 19 families studied, and are summarized in
Table I. The overall detection rate of the disease-causing
sequence variants was 77%. At least one mutation was
found in 16 individuals (84%). Nine new mutations were
identified. Among these, five are missense mutations (R391G,
A766D, D1238H, L1335P, E1400K), one is a nonsense
mutation (W1223X), one is a small in-frame deletion of 33 bp
(1088–1120del), and two are predicted to impair splicing
(V74del, IVS25-3C4A).
All new mutations but three (R391G identified in family
15, D1238H identified in family 11, and E1400K identified in
families 1 and 3) fulfil the criteria described for defining
nucleotide sequence variants as disease-causing (Cotton
and Scriver, 1998). Although R391, D1238, and E1400 are
not fully conserved among the 12 known human ABCC
proteins (ClustalW program), these mutations cosegregate
with the PXE phenotype in the four families and were not
found in a panel of 200 alleles from unaffected control
individuals. R391 was considered as a conserved amino
Abbreviations: ABC, ATP-binding cassette; PXE, pseudoxanthoma
elasticum
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Table I. Phenotype and genotype of the patients studied
Patient Origin Sex Age (y) Amino acid variation Nucleotide variation Exon
Phenotype
C O CV
1 France/Greece F 26 R1141X 3421C4T 24 1 0 0
E1400K 4198G4A 29
2 France F 31 V74del 220-222del 3 1 1 0
V74del 220-222del 3
3-1 Morocco F 20 E1400K 4198G4A 29 1 0 0
E1400K 4198G4A 29
3-2 M 18 E1400K 4198G4A 29 1 0 2
E1400K 4198G4A 29
4 France F 36 A999_S1403del EX23_29del 23–29 1 1 0
Splicing alteration IVS25-3C4A
5 France F 44 ?/? 2 0 0
6 France M 15 R1141X 3421C4T 24 2 0 1
R1141X 3421C4T 24
7 Morocco F 26 R518Q 1553G4A 12 1 1 1
R518Q 1553G4A 12
8 Turkey F 21 A766D 2297C4A 18 1 0 0
A766D 2297C4A 18
9 France F 41 R518Q 1553G4A 12 1 0 0
T1130M 3389C4T 24
10 France F 30 R518X 1552C4T 12 1 0 0
R518X 1552C4T 12
11-1 Algeria F 75 NA 1 0 0
T1130M 3389C4T 24
11-2 M 39 D1238H 3712G4C 26 1 0 0
11-3 F 36 Q363_R373del 1088-1120del 9 2 0 0
D1238H 3712G4C 26
12 France M 58 ?/? 0 2 0
13 France F 50 L1335P/? 4004T4C 28 1 0 0
14 France M 51 ?/? 2 2 1
15 France F 50 R391G 1171A4G 9 1 0 0
A999_S1403del EX23_29del 23–29
16 France M 42 R1138Q 3413G4A 24 1 0 0
R1138Q 3413G4A 24
17 France F 35 R518X/? 1552C4T 12 1 0 0
18 France F 31 R1141X 3421C4T 24 1 0 0
W1223X 3668G4A 26
19-1 France M 18 R1164X/? 3490C4T 24 1 0 0
19-2 M 15 R1164X/? 3490C4T 24 1 0 0
The nine novel mutations are in bold.
C (cutaneous manifestations): 0 —clinically absent but present on biopsy examination, 1 —moderate skin lesions (neck and folds), 2 —extended skin
lesions.
O (ophthalmologic manifestations): 0 —absence (absence of angioid streaks or absence of neovascularization),
1 —angioid streaks with neovascularization or visual impairment, 2 —central blindness.
CV (cardiovascular manifestations): 0 —absence or pulse abolition, 1 —symptomatic (arteriosclerosis), 2 —hemorrhagic or ischemic complication.
NA: not available.
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acid among 11 ABCC proteins (ABCC1 to ABCC11), but as
non-conserved when ABCC12 was added. ABCC12, how-
ever, encodes an unusual ABC protein without the second
ATP-binding domain and contains only four membrane-
spanning regions in the carboxyl half of the protein (Bera
et al, 2002). Therefore, R391G was assumed to be disease-
causing. D1238H and E1400K drastically change the charge
of residues located close to (D1238H) or in (E1400K) the
second nucleotide binding domain (NBD2) of the molecule,
where mutational analysis in ABC transporters has often
been shown to lead to impaired function (Kerb et al, 2001).
For these reasons, D1238H and E1400K were assumed to
be pathogenic mutations.
This study is the largest PXE study of families of French
origin (15 families). The two known recurrent mutations
(R1141X and EX23_29del) account respectively for 13%
and 7% of the mutations detected in the French families
included in our study, and were absent from the families
originating from Algeria, Morocco, and Turkey. In our cohort,
we found that arginine codon 518 is a new recurrent
mutated amino acid, corresponding to 23% of the muta-
tions detected in the family studied (11.5% for R518X and
11.5% for R518Q).
Nine of the mutations that we identified are novel. The
nonsense mutation (W1223X), and the mutations predicted
to impair exon 3 and exon 26 splicing (V74del, IVS25-
3C4A) predict the production of a truncated protein,
provided that the mutated mRNA is stable. The 33 bp
deletion (1088–1120del) leads to the deletion of 11 amino
acids located in transmembrane and intracellular domains.
All the five novel missense mutations are located within
intracellular domains of the molecule, three in the nucleotide
binding domains (A766D in NBD1, L1335P and E1400K in
NBD2) and two in a cytoplasmic loop (R391G, D1238H).
Two of the mutations (D1238H in family 11 and IVS25-
3C4A in family 4), located in exon 26 and its flanking
intronic sequences, were not detected by dHPLC, and were
identified only after direct sequencing of all 31 exons of
ABCC6. The lack of detection of these mutants by dHPLC
could be due to the observed complex melting curve of the
corresponding amplimer. The detection rate in our study is
0.72 when only screening by dHPLC is used, and 0.77 when
screening by dHPLC and systematic direct sequencing are
combined. This detection rate is higher than in previous
reports. Possible reasons for the lack of detection in some
patients could be due to exonic deletions (i.e., deletion of
exon 15 (Le Saux et al, 2001)), splice site mutations distant
from the coding sequence (i.e., mutation 1811þ1.6 kb in
the ABCC7/CFTR gene (Reboul et al, 2002)), or mutation in
the regulatory sequences of the gene.
Haplotype analysis We performed haplotype analysis to
identify a possible founder origin of mutations found in our
study. The results are summarized in Table II. The recurrent
mutated allele R1141X shares a common haplotype
identical-by-descent in the French families (families 1, 6,
and 18), which is consistent with the same geographic
origin of these patients. R1141X is the most frequent
mutation found in the European population, and haplotype
analysis of additional European patients would be helpful to
establish whether this mutant allele is inherited from a
common ancestor. Haplotype analysis of the two French
families (families 4 and 15) sharing the recurrent mutation
EX 23_29del reveals different alleles, identical-by-state. This
mutation is mainly identified in the North-American popula-
tion in which an identical-by-descent mutated allele could
not be excluded. Haplotype analysis in families homozy-
gous for a mutation shows common haplotypes, consistent
with the known consanguinity (families 2, 3, 7, and 8), or
suggestive of unknown consanguinity (families 6, 10, and
16). Haplotypes identified in these families are different from
the one associated with the same mutations in family 9
(R518Q), family 17 (R518X), and family 1 (E1400K), sugges-
ting that they do not share a common founder with these
families.
Genotype–phenotype correlation The clinical features of
the patients are summarized in Table I together with the
mutations identified. Regarding the high degree of allelic
heterogeneity and the small size of the cohort, it was
difficult to make correlations between the phenotype and
the nature or the position of the mutations. In our study,
homozygosity or compound heterozygosity for mutations
leading to a premature stop codon (families 2, 4, 6, 10, and
18) was not significantly associated with a more severe
phenotype. Among the missense mutations we identified,
E1400K was associated with a high intra-familial phenotypic
variation in family 3, suggestive of the contribution of other
factors to the phenotype severity. Specifically, in this family
the sister has typical skin lesions without cardiovascular or
ocular involvement, whereas the brother has typical skin
lesions associated with severe cardiovascular disease
manifestations (multiple ischemic cerebral strokes during
his infancy, renal and hepatic diffuse arteritis, internal
carotid and iliac artery stenosis, and an episode of gastro-
intestinal hemorrhage). No other cause of cardiovascular
disease was identified in this patient; in particular, the
search for hemoglobinopathy, protein C and protein S
deficiencies was negative. The two sibs had no major differ-
ences in nutritional, lifestyle, environmental factors, or
medical history, suggesting the implication of the genetic
background in the genotype variability.
Mode of inheritance PXE was first described as a
sporadic disorder, but both autosomal recessive and auto-
somal dominant inheritances have been observed (Pope,
1975; Neldner, 1988; Bergen et al, 2000). No family with PXE
transmitted through three generations has been published
however, and both dominant and recessive forms of PXE
have been linked to the same chromosomal region 16p13.1
(Struk et al, 1997). Since the implication of ABCC6
mutations in PXE, no specific dominant mutation has been
described. One family (family 11) in our cohort was first
suggestive of dominant inheritance (Fig 1). Surprisingly, the
molecular analysis found three different mutations in the
two sibs: one was a compound heterozygote for T1130M
and D1238H, while the other was a compound heterozygote
for a 33 bp deletion in exon 9 (1088–1120del) and D1238H.
The mother who was affected with PXE declined genetic
analysis. The father was deceased and his status for PXE
was unknown. On the basis of our molecular results
however, each sib has probably inherited one of the two
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putative maternal mutated alleles (T1130M or 1088–
1120del). We suggest that the mutated allele D1238H
shared by both affected offspring has been inherited from
the father, leading to recessive inheritance. Thus, this family
would correspond to a case of pseudodominance. Another
case of pseudodominant PXE has previously been proved
by molecular analysis of ABCC6 in a consanguineous family
(Ringpfeil et al, 2000). ABCC6 mutations have been re-
ported in three families with apparently dominant PXE. In two
families, the recurrent recessive mutation R1141X was
identified in affected patients (Bergen et al, 2000). In a third
family, the three affected sibs were heterozygous for the
maternal inherited R1495C mutation. Autosomal recessive
inheritance could not be excluded in this family, however, as
the three patients inherited the same paternal allele (Hu
et al, 2003). In fact, no molecular evidence for autosomal
dominant inheritance has been demonstrated at present,
although some of the heterozygous carriers may demon-
strate minimal manifestation of the disease (Sherer
et al, 2001). Taken together, these data support a unique
recessive mode of inheritance in PXE.
In summary, we have identified nine novel mutations in
patients with PXE, adding to the ABCC6 mutation database.
No clear delineation of genotype/phenotype correlation was
identified and we observed a marked intra-familial pheno-
typical variation in one family. Our study and previous publica-
tions further support an exclusively autosomal recessive
mode of inheritance for PXE. This information should help
clinicians for genetic counselling.
Materials and Methods
Patients A cohort consisting of 19 families with PXE was studied.
The diagnosis was based on dermatological examination in
combination with ophthalmological and cardiovascular evaluation.
In each patient, the diagnosis was confirmed by histopathology
examination of a skin biopsy combined with special stains for
elastin (Verhoeff–van Gieson) and/or for calcium (von Kossa). The
majority of the families (15 of 19) originated from France. In three
families, two or more individuals were affected. Consanguinity was
known in only four families (families 2, 3, 7, and 8) (Table I).
Mutation detection After informed consent for inclusion in the
study, DNA was isolated by standard procedures from the
peripheral blood of patients affected with PXE, from their
unaffected relatives, and from clinically healthy unrelated indivi-
duals. Intron-derived primers specific for PCR amplification of
ABCC6 exons 1–9 (which do not amplify the two truncated
pseudogenes ABCC6j1 and ABCC6j2) were synthesized using
sequences previously reported (Pulkkinen et al, 2001). Intron-
derived primers for PCR amplification of ABCC6 exons 10–31
were synthesized using sequence information from BAC clone
CIT987SK-A-962B4 containing ABCC6 (GenBank accession num-
ber U91318). Primers are available upon request to the authors.
Intron/exon boundaries were deduced from information available
from the Institute for Genome Research database and by
comparison with the ABCC6 cDNA sequence (GenBank accession
number NM_001171). PCR products were analyzed by denaturing
high-performance liquid chromatography (dHPLC), followed by
automated sequencing of the PCR products displaying an
abnormal elution profile. EX23_29del was screened by PCR using
a previously described set of nested primers (Le Saux et al, 2001).
All 31 exons of ABCC6 were sequenced in patients who had
only one or no mutant alleles identified after mutation screening by
dHPLC.
Haplotype analysis Haplotype analysis was performed for muta-
tion identified in at least two families, using two microsatellite
markers D16B9621 and D16B9622 closely linked to ABCC6 (Cai
et al, 2000) and nine intragenic single-nucleotide polymorphisms
(1841T4C, 1890C4G, 1896C4A, IVS13-86G4T, IVS14-92delG,
IVS14-90G4T, IVS14-57G4A, IVS30-76A4G, IVS30-30G4A).
Clinical investigation was carried out in Orle´ans and Toulouse (France),
and mutation identification was performed in Toulouse (France).
DOI: 10.1111/j.0022-202X.2004.22312.x
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